Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer

Oncologist

Volumn 16, Issue 7, 2011, Pages 935-941

  Brewster, Abenaa M ^a   Parker, Patricia A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast neoplasm; Decision making; Mastectomy; Prognosis; Psychosocial factors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CLINICAL DECISION MAKING; CONTRALATERAL PROPHYLACTIC MASTECTOMY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; GENE MUTATION; HEALTH CARE COST; HUMAN; MASTECTOMY; OVERALL SURVIVAL; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UNITED STATES;

BREAST NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; MASTECTOMY; PATIENT SATISFACTION; RISK FACTORS;

EID: 79960885823     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0022     Document Type: Review

References (58)

1. Tuttle TM, Habermann EB, Grund EH et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol 2007;25:5203-5209.
2. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010;11:CD002748.
3. Kollias J, Ellis IO, Elston CW et al. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 1999;25:584-589.
4. Robbins GF, Berg JW. Bilateral primary breast cancer: A prospective clin-icopathological study. Cancer 1964;17:1501-1527.
5. Healey EA, Cook EF, Orav EJ et al. Contralateral breast cancer: Clinical characteristics and impact on prognosis. J Clin Oncol 1993;11:1545-1552.
6. Rosen PP, Groshen S, Kinne DW et al. Contralateral breast carcinoma: An assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery 1989;106:904-910.
7. Adami HO, Bergström R, Hansen J. Ageat first primary as adeterminant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer 1985;55:643-647.
8. Schairer C, Brown LM, Mai PL. Inflammatory breast cancer: High risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Res Treat 2011 Mar 9. [Epub ahead of print].
9. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
10. Thürlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
11. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351: 1451-1467.
12. Metcalfe K, Lynch HT, Ghadirian P et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-2335.
13. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271.
14. Frost MH, Slezak JM, Tran NV et al. Satisfaction after contralateral prophylactic mastectomy: The significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 2005;23:7849-7856.
15. Montgomery LL, Tran KN, Heelan MC et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 1999;6: 546-552.
16. Tuttle TM, Jarosek S, Habermann EB et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 2009;27:1362-1367.
17. McLaughlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy: Trends in use from 1995 through 2005. Cancer. 2009;115:5404-5412.
18. Arrington AK, Jarosek SL, Virnig BA et al. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol 2009;16:2697-2704.
19. Jones NB, Wilson J, Kotur L et al. Contralateral prophylactic mastectomy for unilateral breast cancer: An increasing trend at a single institution. Ann Surg Oncol 2009;16:2691-2696.
20. Stucky CC, Gray RJ, Wasif N et al. Increase in contralateral prophylactic mastectomy: Echoes of a bygone era? Surgical trends for unilateral breast cancer. Ann Surg Oncol 2010;17(suppl 3):330-337.
21. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
22. Recht A. Contralateral prophylactic mastectomy: Caveat emptor. J Clin Oncol 2009;27:1347-1349.
23. Boughey JC, Hoskin TL, Degnim AC et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 2010;17:2702-2709.
24. Van Sprundel TC, Schmidt MK, Rookus MA et al. Risk reduction of con-tralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005;93:287-292.
25. Herrinton LJ, Barlow WE, Yu O et al. Efficacy ofprophylactic mastectomy in women with unilateral breast cancer: A cancer research network project. J Clin Oncol 2005;23:4275-4286.
26. Peralta EA, Ellenhorn JD, Wagman LD et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000;180:439-445.
27. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010;102:401-409.
28. Lee JS, Grant CS, Donohue JH et al. Arguments against routine contralat-eral mastectomy of undirected biopsy for invasive lobular breast cancer. Surgery 1995;118:640-647.
29. Giuliano AE, Boolbol S, Degnim A et al. Society of Surgical Oncology: Position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol 2007;14:2425-2427.
30. Yi M, Hunt KK, Arun BK et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) 2010;3:1026-1034.
31. Polednak AP. Frequency of prophylactic contralateral mastectomy among breast cancer patients. J Am Coll Surg 2001;192:804-805.
32. Sorbero ME, Dick AW, Beckjord EB et al. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009;16:1597-1605.
33. Biglia N, Bounous VE, Martincich L et al. Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast. Eur J Surg Oncol 2011;37: 199-204.
34. Bedrosian I, Mick R, Orel SG et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003;98:468-473.
35. Bilimoria KY, Cambic A, Hansen NM et al. Evaluating the impact of pre-operative breast magnetic resonance imaging on the surgical management of newly diagnosed breast cancers. Arch Surg 2007;142:441-445.
36. Spear SL, Schwarz KA, Venturi ML et al. Prophylactic mastectomy and reconstruction: Clinical outcomes and patient satisfaction. Plast Reconstr Surg 2008;122:1-9.
37. Geiger AM, West CN, Nekhlyudov L et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 2006;24:1350-1356.
38. Schwartz MD. Contralateral prophylactic mastectomy: Efficacy, satisfaction, and regret. J Clin Oncol 2005;23:7777-7779.
39. Litton JK, Westin SN, Ready K et al. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 2009;115:1598-1604.
40. Nekhlyudov L, Bower M, Herrinton LJ et al. Women's decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr 2005;(35):55-60.
41. Graves KD, Peshkin BN, Halbert CH et al. Predictors and outcomes of con-tralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat 2007;104:321-329.
42. O'Connor AM, Tugwell P, Wells GA et al. A decision aid for women considering hormone therapy after menopause: Decision support framework and evaluation. Patient Educ Couns 1998;33:267-279.
43. O'Connor AM, Jacobsen MJ, Stacey D. An evidence-based approach to managing women's decisional conflict. J Obstet Gynecol Neonatal Nurs 2002;31:570-581.
44. Fagerlin A, Lakhani I, Lantz PM et al. An informed decision? Breast cancer patients and their knowledge about treatment. Patient Educ Couns 2006;64: 303-312.
45. Fox SA, Heritage J, Stockdale SE et al. Cancer screening adherence: Does physician-patient communication matter? Patient Educ Couns 2009;75: 178-184.
46. Chen JY, Tao ML, Tisnado D et al. Impact of physician-patient discussions on patient satisfaction. Med Care 2008;46:1157-1162.
47. Gershenwald JE, Hunt KK, Kroll SS et al. Synchronous elective contralat-eral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol 1998;5:529-538.
48. Borgen PI, Hill AD, Tran KN et al. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998;5:603-606.
49. Anderson K, Jacobson JS, Heitjan DF et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006;144:397-406.
50. Norum J, Hagen AI, Maehle L et al. Prophylactic bilateral salpingo-oopho-rectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: A cost-effectiveness analysis. Eur J Cancer 2008;44:963-971.
51. Grann VR, Panageas KS, Whang W et al. Decision analysis of prophylactic mastectomy and oophorectomyinBRCA1-positiveor BRCA2-positive patients. J Clin Oncol 1998;16:979-985.
52. Gold M. Panel on cost-effectiveness in health and medicine. Med Care 1996;34(12 suppl):DS197-DS199.
53. Cartwright WS. Methods for the economic evaluation of health care programmes, second edition. ByMichaelF.Drummond, Bernie O'Brien, Greg L. Stoddart, George W. Torrance. Oxford: Oxford University Press, 1997. J Ment Health Policy Econ 1999;2:43.
54. Barton MB, West CN, Liu IL et al. Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr 2005;(35):61-66.
55. Gold M, Siegel J, Russell L et al. Cost Effectiveness in Health and Medicine. New York: Oxford University Press, 1996:197-199.
56. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, Third Edition. New York: Oxford University, 2005:55.
57. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: Economic cost and quality of life. Annu Rev Public Health 2001;22:91-113.
58. Helzlsouer KJ. Contralateral prophylactic mastectomy: Quantifying benefits and weighing the harms. J Clin Oncol 2005;23:4251-4253.